Immunosuppressants or new anchors for band-buying competitive landscape sit back.

Band procurement has been implemented three batches, industry shocks continue.
throughout the entry of the volume of procurement of original research varieties - Porivi, Lipto, BoLuding, Ereza, all in a short period of time fell to the altar.
the State Health Insurance Administration's unwavering cost control growth, before the Health Insurance Bureau recruitment of The Secretary of the First Lei also admitted that the rolling attention to the head varieties, "only large varieties of prices down, the burden of the people can be reduced."
analyzed the previous batch of the finalists in the purchase of the volume, most of which meet the conditions such as large-scale general name, many competitive varieties, and consistency of generic drug consistency evaluation.
so, for immunosuppressants such a large number of head varieties, fierce competition, and patients need long-term drug use of the large market, belt procurement will bring what kind of game to promote market restructuring? We will use a series of articles to analyze and pre-judge the trend of the future immunosuppressant market under the pre-determined band purchase.
with the rapid development of China's economy, medical technology is changing rapidly, once let us helpless many end-stage diseases, can now be through organ transplantation to give patients treatment opportunities.
2019, there will be more than 20,000 liver, kidney, heart and lung transplants.
transplants give patients a new lease of life, and with it comes the need to take anti-rejection drugs for long periods of time to protect organs.
the number of immunosuppressants in China is still growing rapidly after reaching the 5 billion market size in 2015, reaching 11.51% in 2015-2019.
its ATC classified anti-oncology and immunomodulator sales growth contribution rose to 25.4% in 2019, or 1-4 percent of the total prescription drug market.
is why this category continues to enter the field of view of band procurement.
immunosuppressant market consists mainly of three types of drugs, namely, basic immunity, combined immunity and induced immunity.
the first two are used after surgery and require long-term medication, while induced immunity is used more in the perioperative period.
basic immunosuppression accounted for half of the overall market, common drugs for his kermos, cyclosporine, etc. , on behalf of varieties such as Astellas' Plecofu, Novartis's New Mountain Ming, East China Pharmaceuticals' Seifok, New Seth equality.
Figure 1 Overview of the competitive landscape of immunosuppressants is the clinical use of two or more anti-rejection drugs to achieve therapeutic purposes.
the main role in the joint immune market is the promcoxele - after liver and kidney transplants, doctors prescribe them mostly in combination with promcphenols and basic immunosuppressants.
is the demcphenol is considered to be the main drug treatment method of the future anti-rejection market, the size of the category accounts for about 35% of the overall immunosuppressant market, representing varieties such as Roche's, China and east China's Sai Keping, Haizheng Pharmaceuticals, such as the sein energy.
Figure 2 Immunosuppressant Part of the competitive pattern from the market pattern is not difficult to see, Roche's insight as a joint immunosuppressive treatment field head varieties, sales of more than 1 billion, is likely to become the next batch of belt procurement of varieties anchor.
, who was listed in China in October 1999 for more than 20 years, is a true veteran of immunosuppressants.
however, in the recent hanging net procurement - Gansu Province hanging network procurement published prices, it is noted that 0.25g capsule regulations are still at the price of 540.29 yuan / grain hanging net, to maintain the highest price in the category, and far higher than the generic consistent evaluation of the vegetarian energy (same product regulations, Haizheng Pharmaceuticals) 215.91 yuan and the highest sales of the category can be flat (same dose, scattered film, China east China) 258 yuan.
Figure 3, the main varieties of McCorphenolest 2017-2020 winning price range (oral agent, 250mg/40 tablets) is also because of the price of the single-product hanging net of mcCorphenolest has always maintained a high, patientcompli with strong advantages, over the years, the domestic generic drug declaration fierce abnormal.
According to GBI data, there are 44 companies that have now been approved for listing, and four more are in CDE listing applications.
in the volume of procurement normalization - product expansion, regional expansion, winning varieties of the market today, "full competition in the sun" has become the future of medicine the way. can the
still maintain a firm unit price in a rapidly surging market? Will the third batch of band purchases include anti-rejection drugs? If the amount of purchase, how to take the drug population to face the switch of varieties? How will enterprises producing anti-rejection varieties prepare to cope with the inevitable arrival of band purchases? And the answers to the questions, we'll continue to delving into the questions in the next few pages.
.